Benitec Biopharma publishes FY2026 annual report
BNTC•FY2026 annual report highlights BB-301 progress
Benitec annual report highlighted progress for BB-301 in OPMD-related dysphagia, with Cohort 1 follow-up completed.
Cohort 2 enrollment finished, with three high-dose patients treated without safety issues reported.
FDA Type C meeting held in 3Q2026 to align on pivotal study design; minutes expected in October.
Interim Phase 1b/2a data slated for late-breaking presentation at ESGCT on Oct. 27-30, 2026.
Pivotal BB-301 trial initiation targeted for mid-2027; cash position of USD 180 million cited as supporting execution.
